Efficacy of novel agents in r/r T pro-lymphocytic leukaemia.

Prof Staber speaks with ecancer at EHA 23 about the management TPLL, a rare blood disease, with new agents.

He describes the challenges in trial design for rare diseases, and the drug screening panel used in this assessment to determine the likely activity of ibrutinib.

For more on trial design for rare diseases, watch Dr Gianni Bisogno discuss a trial for rhabdomyosarcoma at ASCO 2018.